Aesth Plast Surg (2019) 43:1408–1409
https://doi.org/10.1007/s00266-019-01377-7

LETTER TO THE EDITOR

Letter to the Editor on Managing Pathologic Scars by Injecting Auto-Cross-Linked Hyaluronic Acid: A Preliminary Prospective Clinical Study

Zi-Li Sun[1,3] · Yi Feng[2] · Feng-Lai Yuan[1,3] · Guo-Zhong Lv[1,3]

Received: 9 April 2019 / Accepted: 11 April 2019 / Published online: 22 April 2019

Level of Evidence V This journal requires that authors assign a level of evidence to each article. For a full description of these Evidence-Based Medicine ratings, please refer to the Table of Contents or the online Instructions to Authors www.springer.com/00266.

Dear Editor,

Recently, we read the article by Riccio et al. [1] which confirmed that IAL-SYSTEM ACP, an auto-cross-linked hyaluronic acid-injectable formulation, injection is an effective and safe treatment for pathologic scar. From the date and images of this innovative study, we can obviously observe the differences before and after treatment. In addition, Riccio et al. chose a quite suitable scar evaluation tool to assess whether IAL-SYSTEM ACP is effective [2]. Thus, we think this study is important for the future development of scar treatment. However, from our point of view, there are still some inadequacies in this article.

First, as clinical research, the sample size of IAL-SYSTEM ACP-treated pathologic scars was small. This little disadvantage may influence the credibility of the article. And Riccio et al. might need more treatment cases for follow-up observation [3].

Second, we observed that this article focuses on observing differences before and after IAL-SYSTEM ACP treatment, a single-mode treatment. In recent years, there have been many effective treatments for pathologic scars, such as the application of 5-fluorouracil, retinoic acid, tamoxifen, bleomycin and so on [4]. The results may have been more convincing if the authors had added another treatment as a control to compare with the effect of treatment with IAL-SYSTEM ACP.

Taken together, these data demonstrate that IAL-SYSTEM ACP treatment has beneficial effects in pathologic scar management, which also suggests a potential clinical application for pathologic scars.

Compliance with Ethical Standards

Conflict of interest The authors declare that they have no conflicts of interest to disclose.

Human and Animal Rights This article does not contain any studies with human participants or animals performed by any of the authors.

Informed Consent For this type of study, informed consent is not required.

References

1. Riccio M et al (2019) Managing pathologic scars by injecting auto-cross-linked hyaluronic acid: a preliminary prospective clinical study. Aesthetic Plast Surg 43(2):480–489
2. van de Kar AL et al (2005) Reliable and feasible evaluation of linear scars by the Patient and Observer Scar Assessment Scale. Plast Reconstr Surg 116(2):514–522
3. Guix B et al (2001) Treatment of keloids by high-dose-rate brachytherapy: a seven-year study. Int J Radiat Oncol Biol Phys 50(1):167–172

✉ Feng-Lai Yuan
bjjq88@163.com

✉ Guo-Zhong Lv
544096718@qq.com

[1] Wuxi Clinical Medicine School of Integrated Chinese and Western Medicine, Nanjing University of Chinese Medicine, Wuxi 214041, China

[2] Department of Pharmacology, Medical School, Yangzhou University, Yangzhou 225001, China

[3] Department of Orthopaedics and Central Laboratory, The Third Hospital Affiliated to Nantong University, Wuxi 214041, Jiangsu, China

4. Berman B, Maderal A, Raphael B (2017) Keloids and hypertrophic scars: pathophysiology, classification, and treatment. Dermatol Surg 43(Suppl 1):S3–S18